Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – Molecular bilayer structure
Patent
1976-12-17
1979-07-17
Fagelson, Anna P.
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
Molecular bilayer structure
23230B, 424 1, 424 12, 424 13, G01N 2100, G01N 3100, G01N 3316
Patent
active
041615158
ABSTRACT:
A novel sensitive method for determining qualitatively and quantitatively the presence of a wide variety of physiologically active organic compounds (ligand) and their receptors is provided. The method employs a reagent which involves bonding a compound having structural similarity to the compound to be determined (ligand analog) to a fluorescing compound. The unknown compound is referred to as a ligand, the conjugate of the structurally similar compound and fluorescer is referred to as ligand analog-fluorescer, and compounds which recognize a specific structure and bind to such structure are referred to as receptors and are normally antibodies.
The fluorescer which is chosen will have either a change in quantum yield or a change in its emission and/or absorption spectra or all of them, when bound to antibody, as compared to being unbound. For the purposes of the assay, all that is required is that there be a change in the emission intensity at some wavelength or band of wavelengths.
The rate at which fluorescer antibody binds to the fluorescer portion of the ligand analog-fluorescer or the amount of fluorescer antibody bound to the fluorescer portion of the ligand analog-fluorescer at equilibrium will be related to the amount of ligand antibody bound to the ligand analog portion of the ligand analog-fluorescer. Therefore, by combining antibodies to both ligand and fluorescer, with ligand analog-fluorescer and an unknown, one can determine the amount of ligand present in the unknown by relating the emission intensity at a particular wavelength or band of wavelengths to standards.
Alternatively, by combining an unknown containing antiligand with fluorescer antibody and ligand analog-fluorescer, one can determine the amount of receptor in the unknown.
REFERENCES:
patent: 3641235 (1972-02-01), Weiss
patent: 3720760 (1973-03-01), Bennich
patent: 3901654 (1975-08-01), Gross
patent: 3998943 (1976-12-01), Ullman
Dandliker, Immunochem., vol. 7, 1970 pp. 799-828.
Fagelson Anna P.
Rowland Bertram I.
Syva Company
LandOfFree
Double receptor fluorescent immunoassay does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Double receptor fluorescent immunoassay, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Double receptor fluorescent immunoassay will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-317479